Mutations affecting the BRAF gene were present in approximately 8–12% of metastatic colorectal cancer; BRAF is a key driver gene of mitogen-activated protein kinase (MAPK) activation, and its mutations are associated with a poorer response to standard treatments and worse prognosis [72,73]. The gene discussed is BRAF; the disease is metastatic colorectal cancer.